A Randomized, Double-Blind, Single-Dose Study Comparing the Biosimilarity of HOT-1010 With Bevacizumab (Avastin®) in Chinese Healthy Male Subjects
Objective: This study was conducted to compare the pharmacokinetics, safety and immunogenicity of HOT-1010 with bevacizumab (Avastin®) in Chinese healthy male subjects.Methods: A single-center, randomized, double-blind, single-dose, parallel trial was performed in 84 Chinese healthy male subjects wh...
Main Authors: | Kai Huang, Linling Que, Ying Ding, Nannan Chu, Zhenzhong Qian, Yunfei Shi, Wei Qin, Zhenni Li, Yuanxin Chen, Xianghong Gu, Jiakun Wang, Lin Zhang, Jisheng Zhang, Xiangyang Zhu, Yongmin Yang, Yuan Tang, Qing He |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2021-06-01
|
Series: | Frontiers in Pharmacology |
Subjects: | |
Online Access: | https://www.frontiersin.org/articles/10.3389/fphar.2021.694375/full |
Similar Items
-
Toxicity and efficacy of biosimilar bevacizumab in the second-line therapy for metastatic colon cancer in routine clinical practice: results of an independent observational study
by: M. Yu. Fedyanin, et al.
Published: (2021-06-01) -
Structural and Functional Analysis of CEX Fractions Collected from a Novel Avastin<sup>®</sup> Biosimilar Candidate and Its Innovator: A Comparative Study
by: Busra Gurel, et al.
Published: (2022-07-01) -
Multidose bevacizumab (Avastin) vial microbial safety: A real-life scenario
by: Battu Aneesha Priya, et al.
Published: (2021-01-01) -
A Phase I, Randomized, Single-Dose Study Evaluating the Biosimilarity of TAB008 to Bevacizumab in Healthy Volunteers
by: Jin Wang, et al.
Published: (2019-08-01) -
VISUAL OUTCOME AFTER INTRAVITREAL BEVACIZUMAB (AVASTIN) IN THE TREATMENT OF BRANCH RETINAL VEIN OCCLUSION
by: Saquib Naeem, et al.
Published: (2019-04-01)